Business / Finance

RSS

Akorn's consolidated revenue for fourth quarter 2013 increases 19% to $85 million

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year-ended December 31, 2013.

3 Mar 2014

Magellan Health Services reports net revenue of $3.5 billion for fourth quarter 2013

Magellan Health Services, Inc. today reported financial results for the fourth quarter and full year 2013, as summarized below.

3 Mar 2014

Roark Capital Group invests in Anytime Fitness

Anytime Fitness, the world's largest and fastest-growing co-ed fitness franchise, today announced that an affiliate of Roark Capital Group, an Atlanta-based private equity firm that focuses on investing in the franchise industry, has made an equity investment in the company.

3 Mar 2014

RainDance Technologies closes $16.5 million Series E financing round

RainDance Technologies, Inc., an innovative genomics tools company making molecular testing of complex diseases more standardized and readily available, today announced that it has closed a $16.5 million Series E financing round extension. New investors include GE Ventures and Northgate Capital; all existing financial investors also participated in this round of financing.

3 Mar 2014

Aetna announces quarterly cash dividend, sanctions additional repurchase of common stock

The Board of Directors of Aetna declared a quarterly cash dividend of $0.225 per share on the company's common stock.

3 Mar 2014

Astellas Pharma to exclusively commercialize isavuconazole in the U.S. and Canada

Astellas Pharma Inc. announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd.

28 Feb 2014

Dyax reports total revenues of $16.9 million for fourth quarter 2013

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2013.

28 Feb 2014

HMS Holdings' fourth quarter revenue decreases 8.6% to $121.6 million

HMS Holdings Corp. today announced financial and operating results for the fourth quarter and full year ended December 31, 2013.

28 Feb 2014

Perrigo Company acquires basket of value-brand OTC products in Australia

Perrigo Company plc announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc. for $51 million in cash.

28 Feb 2014

Abingworth announces final closing of £225M ($375M) fund

Abingworth, the international investment group dedicated to life sciences and healthcare, today announced the final closing of its £225m ($375m) fund, Abingworth Bioventures VI (ABV VI). ABV VI, Abingworth's 10th life sciences fund, exceeded its target of £200 million and invests in life sciences and healthcare both in Europe and the US.

28 Feb 2014

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.

28 Feb 2014

Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Endo Health Solutions today reported fourth quarter 2013 revenues of $585 million, compared to $750 million for the same quarter of 2012.

28 Feb 2014

Ortho Development receives FDA clearance for patented Knee Articulating Spacer Molds

Ortho Development Corporation has received FDA clearance for its patented KASM Knee Articulating Spacer Molds. KASM is a cement spacer mold intended for use in treating patients who develop an infection after undergoing total knee replacement surgery.

28 Feb 2014

Vétoquinol acquires Bioniche's Animal Health business

Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million.

28 Feb 2014